Publications by authors named "Zi-ping Xie"

Inflammation parameters were verified to predict clinical outcomes of metastatic renal cell carcinoma (mRCC) patients treated with tyrosine kinase inhibitors (TKIs). Here, we developed a novel marker, lactate dehydrogenase (tumor burden marker) to lymphocytes (inflammation marker) ratio (LLR), aimed to reveal the prognostic role of LLR for mRCC patients treated with TKIs. We collected clinical data of mRCC patients treated with TKIs.

View Article and Find Full Text PDF

Objective: To explore the feasibility, safety and clinical effect of mid-frequency transcutaneous electrical acupoint stimulation (TEAS) combined with oral tamoxifen (TAM) in the treatment of oligoasthenozoospermia.

Methods: We randomly and equally assigned 120 patients with idiopathic oligoasthenozoospermia to receive oral TAM, mid-frequency TEAS, or TAM+TEAS, all for 8 weeks. Before and after treatment, we recorded the semen volume, total sperm count, sperm concentration, sperm motility, percentage of progressively motile sperm (PMS), and the levels of follicle-stimulating hormone (FSH), luteotrophic hormone (LH) and testosterone (T) in the peripheral serum and compared these parameters among the three groups of patients.

View Article and Find Full Text PDF
Article Synopsis
  • The study aimed to evaluate the effectiveness of combining Paroxetine with mid-frequency electrical pulse acupoint stimulation (EPAS) for treating premature ejaculation (PE) in 69 patients over 8 weeks.
  • Results showed that all treatment groups experienced improved ejaculation latency and reduced PE scores, but the combination of Paroxetine and EPAS had significantly better outcomes, including a 95.7% effectiveness rate.
  • The combination treatment was found to be safer and more effective than using Paroxetine or EPAS alone, as indicated by fewer adverse reactions and greater improvement in symptoms.
View Article and Find Full Text PDF

In this study, one immortalized human normal prostatic epithelial cell line (BPH) and four human prostate cancer cell lines (LNCaP, 22Rv1, PC-3, and DU-145) were treated with Ganoderma Lucidum triterpenoids (GLT) at different doses and for different time periods. Cell viability, apoptosis, and cell cycle were analyzed using flow cytometry and chemical assays. Gene expression and binding to DNA were assessed using real-time PCR and Western blotting.

View Article and Find Full Text PDF